retatrutide phase 3 trial Eli Lilly obesity results 2026 ๐จ HOT OFF THE PRESS:
Description
,
Activating these receptors improves fat metabolism, may protect bone density (a critical concern for lupus patients on corticosteroids), and provides additional cardiovascular benefits
GIP and GLP1 are neuroprotective in preclinical models of neurodegenerative disease
Exenatide reverts the high-fat-diet-induced impairment of BDNF signaling and inflammatory response in an animal model of Alzheimers disease
Challenges: The key challenge for Sanofi is competition from more established and better marketed GLP-1 drugs, particularly those from Novo Nordisk and Eli Lilly
